I. Inigo

发表

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Ping Chen, A. Doweyko, Derek J. Norris, 2004, Journal of medicinal chemistry.

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Zheng Yang, David Kan, F. Lee, 2006, Clinical Cancer Research.

Effects of Androgen on Androgen Receptor Expression in Rat Testicular and Epididymal Cells: A Quantitative Immunohistochemical Study1

I. Huhtaniemi, M. Hardy, C. Bardin, 2000, Biology of reproduction.

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

J. Haidar, M. Kalos, S. Eastman, 2020, Cancer Immunology Research.

Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.

J. Tokarski, B. Koplowitz, J. Hunt, 2005, Bioorganic & medicinal chemistry letters.

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

T. Doman, M. Kalos, J. Manro, 2022, PloS one.

Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model

F. Lee, R. Kramer, T. Wong, 2005, Clinical Cancer Research.

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

J. Haidar, M. Kalos, Leyi Shen, 2020, Molecular Cancer Therapeutics.

BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo

F. Lee, C. Fairchild, R. Borzilleri, 2005 .

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels

F. Luo, S. Castaneda, I. Inigo, 2006, Molecular Cancer Therapeutics.

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668

F. Lee, N. Donato, M. Talpaz, 2004 .

MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

R. Woods, S. Coats, B. Jallal, 2012, International journal of oncology.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

P. Iversen, M. Kalos, G. Plowman, 2018, Journal of Immunotherapy for Cancer.

Abstract A091: Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

M. Kalos, Xiaohong Xu, S. Castaneda, 2016 .

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

M. Kalos, Xiaohong Xu, S. Castaneda, 2015, Journal of Immunotherapy for Cancer.

Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis

Herren Wu, Zhan Xiao, C. Leow, 2013, Molecular Cancer Therapeutics.

Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor

M. Kalos, Xiaohong Xu, B. Anderson, 2017 .

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

F. Lee, R. Kramer, F. Luo, 2005, Cancer Chemotherapy and Pharmacology.

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

F. Lee, R. Borzilleri, F. Luo, 2004 .

Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers

F. Lee, S. Castaneda, I. Inigo, 2005 .

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

F. Lee, R. Borzilleri, L. Lombardo, 2005 .

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

F. Lee, R. Borzilleri, F. Luo, 2004 .